Anita M McGahan
Associate
Dean, Research
Director
of the PhD Programs
Professor and Rotman
Chair in Management
Munk School of
Global Affairs
Senior
Fellow, Massey College
Rotman School of Management
University of Toronto
105 St. George Street
Toronto, ON, Canada M5S
(416) 978-6188, amcgahan@rotman.utoronto.ca
Chief Economist
Division for Global Health and Human
Rights
Division of Emergency Medicine
Massachusetts General
Hospital
Senior Institute Associate
Institute for Strategy and Competitiveness
Harvard Business School
Institute webpage: www.isc.hbs.edu
New:
PLEASE CLICK HERE FOR WHAT I DO AND WHY
A
NEW ARTICLE ON EMBEDDED
INNOVATION
IM
ON BOARD OF UJENZI TRUST, WHICH HAS A REMARKABLE 15-MINUTE VIDEO ABOUT THE
SOUTH SUDAN ON ITS WEBPAGE: www.ujenzi.org
.
TALK
AT TEDxIBYORK ON NOVEMBER 11, 2010 HAS BEEN POSTED HERE.
I spoke about why and how I think business schools have to change fundamentally
to address the most important management issues of our time.
IM
HONORED TO BE PARTICIPATING ON A PANEL ASSESSING CANADA'S STRATEGIC ROLE IN
GLOBAL HEALTH. NEWS RELEASE
HERE.
I'VE
JUST BEEN CROSS APPOINTED TO THE MUNK SCHOOL OF PUBLIC AFFAIRS. An article
in the University of Toronto magazine profiles the School and its
initiatives. Janice Stein (Munk School), Joe
Wong (Munk School), Yu-Ling Cheng (Engineering),
Murray Metcalfe (Engineering), Peter Singer (Medicine) and I are involved in an
initiative to think more deeply about scaling up and integrative innovation in
resource-limited settings.
ARTICLE IN ROTMAN MAGAZINE ON BUSINESS AND HUMAN TRAFFICKING. This
article is part of a large project at the Massachusetts General Hospital's Division of Global Health and Human Rights on trafficking in which I'm
involved. Under the leadership of the Division's Director, Dr Thomas
Burke, the Division has been conducting case studies in eight cities around the
world.
WORK
WITH COSTAS MARKIDES ON INNOVATION TO CHANGE BUSINESS SYSTEMS. Costas
Markides, one of the great scholars in the field of Strategy, is helping me to
understand what it takes to write a book that will have an impact on
practice. I'm incredibly grateful.
RESEARCH ON INTEGRATED INNOVATION AND HEALTH DELIVERY. With colleagues from the McLaughlin-Rotman
Center for Global Health Abdallah Daar and Peter Singer, I've been working on several papers
on innovative health delivery models for the poor. Our collaborator and
frequent leader in this effort, Onil Bhattacharyya, is a colleague at the University of
Toronto's St. Michael's Hospital in the Keenan Research Centre.
RESEARCH ON INDUSTRY INTER-CONNECTEDNESS IN HEALTH. How restrictively designed should
medicines and medical devices be? When should scaled up
technologies be broadcast globally, and when are localized technologies
and practices optimal? How does industry structure inter-relate
with the scaling up challenge? With colleagues at Bocconi,
I'm working on a project in HIV that takes up these questions.
NEW PROJECT WITH DUKE SCHOLARS NEL DUTT, OLGA HAWN,
ELENA VIDAL, RONNIE CHATTERJI and WILL MITCHELL ON BUSINESS INCUBATORS. This fascinating project deals with
the difficult issue of what it takes to create markets from scratch in
resource-limited settings.
CONTINUING RESEARCH WITH ISIN GULER ON GLOBAL
ENTREPRENEURSHIP.
We're continuing to invest in a number of papers that address how venture
capitalists differentially treat entrepreneurs by country.
MARKET FOR SUBCONTRACTING SERVICES TO
THE MILITARY: Joel Baum and I are working on a project on this topic.
RECENT ARTICLES WITH PETER KLEIN, JOE MAHONEY AND
CHRISTOS PITELIS ON PUBLIC-PRIVATE ENTREPRENEURSHIP. Please see my CV for the full
citations. We're interested in understanding how and when innovation in
the public interest may occur in the private sector, and the unique challenges
of public-private cooperation on public objectives.
MGH TEAM WORKING ON MIGRATION. Thomas Burke, Roy Ahn and I of the Massachusetts General Hospital's Division
of Global Health and Human Rights, are co-editing a book on the health of cities
in this century.
PLEASE CLICK HERE FOR MY RECENT ARTICLE IN ROTMAN MAGAZINE ON THE END OF OIL
ORGAN TRANSPLANTATION TODAY: In
the Health & Human Rights Program at the Massachusetts General Hospital's Center
for Global Health, we've been analyzing markets for live organs (mainly
kidneys), which are illegal in most places: Our thinking
has been sparked by a recent debate in the EU about how these markets can be
regulated effectively.
UNDERSTANDING ENSLAVEMENT, EXPLOITATION
AND TRAFFICKING: Thanks to Roy Ahn, Elizabeth Cafferty and Thomas Burke for leadership in the work we're
doing to develop a better understanding of exploitation and trafficking,
particularly of women and children in resource-limited settings: http://www.massgeneral.org/globalhealth/programs.htm#humanRights
LIMITATIONS ON THE
LIMITED-LIABILITY CORPORATION. Thanks to a generous off-cycle
grant from the Rotman School's AIC Institute for
Corporate Citizenship, 15 MBA students have been working with me, Dr Onil Bhattacharyya of St Michael's Hospital, and doctoral
student Jay Horwitz on alternatives to the
limited-liability corporation for delivering new kinds of products and
services, and especially health services. With Dr Bhattacharyya and
other colleagues from the University of Toronto, we're continuing with a study
of alternative business models for health delivery -- and observing some
innovative and creative solutions already.
TRADE BETWEEN ADVANCED COUNTRIES, NOT
INTO AND OUT OF LEAST-DEVELOPED COUNTRIES, ESCALATED AFTER TRIPS.
Mercedes Delgado, Margaret Kyle and I presented a paper at the March 2008 NBER Biolocations conference: "The Influence of TRIPS on Global Trade in
Pharmaceuticals, 1994-2005." Please send me an email if you're
interested in this.
ARE PHARMA COMPANIES DEVELOPING DRUGS
FOR NEGLECTED DISEASES? Margaret Kyle and I are working on a paper that
analyzes how research on pharmaceuticals adjusted after implementation of the
WTO TRIPS agreement, which required patent protections among all WTO member
countries, even those designated as "least developed." The
policy had the potential to stimulate innovation on neglected diseases, but
TRIPS was controversial because it implied high drug prices for poor
people. We want to see if the research on neglected diseases is
occurring.
HERE'S
THE TEXT OF THE IRWIN AWARD TALK THAT I GAVE
AT THE ACADEMY IN AUGUST 2010..